Hepatitis C transmission and infection by orthotopic heart transplantation

Background: The transmission and clinical consequences of hepatitis C viral (HCV) infection acquired by orthotopic heart transplantation (OHT) from an HCV-infected donor to an HCV-naive recipient have not been well described. We report our experience in 5 HCV-naive patients who were transplanted wit h hearts from HCV-positive donors. All transplants occurred within a 1-year period. Method: After cardiac transplantation we retrospectively examined the recip ients' clinical course, liver-associated enzymes, HCV-antibody serology, qu antitative HCV RNA level, and HCV genotype. Results: Five subjects with rapidly deteriorating heart failure and negativ e serum antibodies to HCV received an emergent OHT from a donor known to be infected with HCV. Liver-associated enzymes peaked at 2 to 6 weeks post-tr ansplant: mean peak alanine aminotransferase was 180 U/L (normal, 9 to 52) and aspartate aminotransferase was 111 U/L (normal, 14 to 36). Liver enzyme s had returned to normal limits by 6 and 12 months post-OHT. At a mean 15 m onths after transplantation, only 1 of 5 patients has developed antibodies to HCV, but 4 of 5 have evidence of infection, as shown by serum HCV RNA. N o patient has developed evidence of liver failure. Conclusions: (1) Transmission of HCV from an HCV-positive donor to an HCV-n aive recipient at the time of OHT is likely. (2) Antibodies to HCV post-OHT may remain negative for more than 1 year in these patients. (3) Hepatitis C viral RNA using polymerase chain reaction should be the test of choice fo r diagnosis of HCV infection post-OHT. (4) Hepatitis C viral donor hearts s hould be limit-ed to critically ill patients in extremis until the long-ter m consequences of acquisition of HCV by an OHT recipient are known.